Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.38 |
| ▸ | LTA4H | P09960 | 3/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4971350 | 0.94 | NPY5R (0.39) | DPP4DPP8DPP9CYP2D6HRH1 | |
| SCHEMBL2176405 | 0.87 | DPP4 (0.43) | DPP4DPP8DPP9CYP2D6HRH1 | |
| SCHEMBL19271810 | 0.85 | NOS3 (0.43) | DPP4DPP8DPP9CYP2D6HRH1 | |
| SCHEMBL6103837 | 0.85 | NOS3 (0.43) | DPP4DPP8DPP9CYP2D6HRH1 | |
| SCHEMBL4974460 | 0.85 | MAPK1 (0.33) | NOS3NOS1 | |
| SCHEMBL4480479 | 0.85 | KDM5A (0.34) | DPP4DPP8DPP9CYP2D6HRH1 | |
| SCHEMBL6088399 | 0.83 | NOS3 (0.42) | DPP4DPP8DPP9CYP2D6HRH1 | |
| SCHEMBL868782 | 0.83 | NOS3 (0.42) | DPP4DPP8DPP9CYP2D6HRH1 | |
| SCHEMBL8031217 | 0.83 | NOS3 (0.42) | DPP4DPP8DPP9CYP2D6HRH1 | |
| SCHEMBL867932 | 0.83 | NOS3 (0.42) | DPP4DPP8DPP9CYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612089-B2 | Tetrahydroisoquinolines as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | claimed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | claimed |
| US-20060160840-A1 | N-[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]-2N-(4-chlorophenylaminocarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; thrombosis; inhibits coagulation of a blood sample | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | claimed |
| EP-0739891-B1 | Substituted heterocycles | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | EP | claimed |
| EP-0865430-B1 | 3-(4-SUBST.-PIPERIDINYL-1)-1-(3,4-DICHLOROPHENYL)PROPYL CARBAMATES AND UREAS AND DERIVATIVES AS NOVEL NEUROKININ ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-03-03 | — | — | EP | claimed |
| EP-0680962-B1 | Heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | claimed |
| EP-0709376-B1 | Phenylpiperidino derivatives as neurokinin antagonists | ASTRAZENECA AB (SE) | 2003-07-23 | — | — | EP | claimed |
| EP-0734383-B1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | claimed |
| EP-0865430-A1 | 3-(4-SUBST.-PIPERIDINYL-1)-1-(3,4-DICHLOROPHENYL)PROPYL CARBAMATES AND UREAS AND DERIVATIVES AS NOVEL NEUROKININ ANTAGONISTS | AstraZeneca AB (SE) | 1998-09-23 | — | — | EP | claimed |
| US-5739149-A | TREATING ASTHMA | ZENECA LIMITED (GB) | 1998-04-14 | — | — | US | claimed |
| US-5731309-A | Substituted heteroalkyleneamine neurokinin antagonists | ZENECA LIMITED (GB) | 1998-03-24 | — | — | US | claimed |
| EP-0808303-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-11-26 | — | — | EP | claimed |
| WO-1997019060-A1 | 3-(4-SUBST.-PIPERIDINYL-1)-1-(3,4-DICHLOROPHENYL)PROPYL CARBAMATES AND UREAS AND DERIVATIVES AS NOVEL NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1997-05-29 | — | — | WO | claimed |
| EP-0739891-A2 | Substituted heterocycles | ZENECA LIMITED (GB) | 1996-10-30 | — | — | EP | claimed |
| WO-1996024582-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1996-08-15 | — | — | WO | claimed |
| EP-0709376-A2 | Therapeutic compounds | ZENECA LIMITED (GB) | 1996-05-01 | — | — | EP | claimed |
| EP-0680962-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1995-11-08 | — | — | EP | claimed |
| WO-1995016682-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-22 | — | — | WO | claimed |
| US-7612089-B2 | Tetrahydroisoquinolines as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| WO-1995016682-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160840-A1 | N-[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]-2N-(4-chlorophenylaminocarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; thrombosis; inhibits coagulation of a blood sample | TFPI, F2, TFPI2 | DPP4 332/4885DPP8 566/4885DPP9 378/4885 |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | DPP4 171/4885DPP8 200/4885DPP9 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.